Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Amylyx Pharmaceuticals, Inc. (AMLX) had Return on Equity of -10.36% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-34.39M |
|
-- |
|
-- |
|
$36.03M |
|
$-36.03M |
|
$1.64M |
|
$-34.39M |
|
$-34.39M |
|
$-34.39M |
|
$-34.39M |
|
$-34.39M |
|
$-34.39M |
|
$-36.03M |
|
$-37.15M |
|
93.33M |
|
93.33M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$353.38M |
|
$0.40M |
|
$9.36M |
|
$362.74M |
|
$25.79M |
|
-- |
|
$4.95M |
|
$30.75M |
|
$332.00M |
|
$332.00M |
|
$332.00M |
|
109.77M |
|
| Cash Flow Statement Financials | |
$-95.44M |
|
$-15.43M |
|
$257.24M |
|
$78.84M |
|
$226.16M |
|
$147.32M |
|
$21.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-95.49M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-10.36% |
-10.36% |
|
-9.48% |
|
-10.36% |
|
$3.02 |
|
$-1.02 |
|
$-1.02 |
|